Podium to Practice: Clinical Updates for the Treatment of Patients with CLL from the 2021 Annual Hematology Meeting
Clinical Updates for the Treatment of Patients with CLL from the 2021 Annual Hematology Meeting
Release Date: February 1, 2022
Expiration Date: January 31, 2023
The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with CLL.
After participating in this activity, participants should be better able to:
- Review how patient and disease-related factors such as patient age, performance status, comorbidities, and mutational status impact the choice of therapy for patients with CLL
- Evaluate recent clinical trial data of the safety and efficacy of current and emerging agents and regimens for patients with newly diagnosed CLL
- Assess various approaches to the treatment of patients with relapsed/refractory CLL, including the optimal sequencing of agents
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Method of Participation
There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.
Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Jennifer Woyach, MD
Associate Professor, Division of Hematology
The James Cancer Hospital and Solove Research Institute
The Ohio State University Comprehensive Cancer Center
Consultant: Abbvie, AstraZeneca, Janssen, Morphosys, Pharmacyclics, Loxo, Arqule, and Beigene
Contracted Research: Abbvie, Loxo, Verastem, Karyopharm, Morphosys
Matthew S. Davids, MD, MMSc
Director, Clinical Research, Division of Lymphoma
Associate Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Consultant: Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Bristol-Myers Squibb, Eli Lily, Genentech, Janssen, Merck, Ono Pharmaceuticals, Pharmacyclics, Research to Practice, Takeda, TG Therapeutics, Verastem and Zentalis
Contracted Research: Ascentage Pharma, AstraZeneca, Genentech, MEI Pharma, Novartis, Pharmacyclics, Surface Oncology, TG Therapeutics and Verastem
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
This activity is supported by independent educational grants from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.
Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.